US Patent Issued to POXEL on May 27 for "Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD)" (French, Swiss Inventors)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,310,949, issued on May 27, was assigned to POXEL (Lyons, France).

"Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD)" was invented by Sebastien Bolze (Massieux, France), Pascale Fouqueray (Sins, Switzerland) and Sophie Hallakou-Bozec (Antony, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of autosomal dominant polycystic kidney disease (ADPKD)."

The patent was filed on April 2, 2021, under Application No. 17/915,123.

*For further information, including im...